4-[[(E)-4-oxopent-2-en-2-yl]amino]-1,2-oxazolidin-3-one

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[[(E)-4-oxopent-2-en-2-yl]amino]-1,2-oxazolidin-3-one
• 化学式: C₈H₁₂N₂O₃
• 分子量: 184.19
• InChiKey: DGYLXKOLHICICX-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• An orally administered drug form comprising a polar bioactive agent and an adjuvant
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0036145B1

  公开（公告）日：1985-05-29
• A rectally administered suppository comprising a drug and an adjuvant
  申请人：Merck & Co., Inc.

  公开号：EP0031561B1

  公开（公告）日：1985-04-10
• METHOD FOR TREATING DEMENTIA
  申请人：College of William and Mary

  公开号：US20160235719A1

  公开（公告）日：2016-08-18

  Methods are disclosed for treating dementia, including mild cognitive impairment, via administration of D-cycloserine, or a prodrug thereof, on a tolerance-inhibiting basis. Specifically, by administering D-cycloserine on a tolerance-inhibiting basis, tolerance to D-cycloserine is less likely than would occur via daily administration, enhancing benefits and reducing costs and side effects. Pharmaceutical compositions useful for the treatment of dementia are additionally disclosed.
• US3932439A
  申请人：——

  公开号：US3932439A

  公开（公告）日：1976-01-13
• US4031231A
  申请人：——

  公开号：US4031231A

  公开（公告）日：1977-06-21